Zacks Investment Research Downgrades Natera (NASDAQ:NTRA) to Sell

Zacks Investment Research downgraded shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Several other equities analysts have also recently weighed in on NTRA. Piper Jaffray Companies set a $40.00 price objective on Tapestry and gave the company a buy rating in a research note on Monday, June 10th. BidaskClub cut Virtu Financial from a sell rating to a strong sell rating in a research note on Wednesday, June 12th. Finally, Canaccord Genuity restated an average rating on shares of Kellogg in a research note on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $30.14.



NASDAQ NTRA opened at $26.10 on Wednesday. The company has a fifty day simple moving average of $25.27. Natera has a 12-month low of $11.08 and a 12-month high of $29.62. The company has a current ratio of 1.85, a quick ratio of 1.73 and a debt-to-equity ratio of 20.88. The firm has a market cap of $1.83 billion, a P/E ratio of -12.14 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.05. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. The business had revenue of $66.82 million during the quarter, compared to the consensus estimate of $66.40 million. As a group, sell-side analysts anticipate that Natera will post -2.17 EPS for the current fiscal year.

In other news, insider Jonathan Sheena sold 1,033 shares of Natera stock in a transaction on Monday, June 10th. The stock was sold at an average price of $24.79, for a total transaction of $25,608.07. Following the sale, the insider now directly owns 240,061 shares in the company, valued at approximately $5,951,112.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Matthew Rabinowitz sold 1,418 shares of Natera stock in a transaction on Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $35,152.22. Following the sale, the chairman now owns 1,286,612 shares in the company, valued at $31,895,111.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,311 shares of company stock worth $132,287. Company insiders own 9.29% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. Great West Life Assurance Co. Can raised its stake in shares of Natera by 136.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after purchasing an additional 3,420 shares during the period. Legal & General Group Plc raised its stake in shares of Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares during the period. Focused Wealth Management Inc bought a new stake in shares of Natera during the 2nd quarter worth $83,000. BNP Paribas Arbitrage SA raised its stake in shares of Natera by 827.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock worth $163,000 after purchasing an additional 7,047 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Natera by 431.9% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock worth $166,000 after purchasing an additional 9,636 shares during the period. Institutional investors own 80.27% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: What is a Derivative?

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.